Google
 
Google

World Stem Cell Summit 2010

Sunday, April 20, 2008

2 stem cell patents issued last week

 

View this message online

Dear manoj kumar valluru,

Last week 2 patents of relevance to the area of stem cells were issued.

  1. # 7,357,929 (Patent Spotlight), teaches antibodies to placental growth factor are useful agains osteoporosis.
  2. # 7,358,082 discloses a new device for culturing cells.

 


Placental growth factor as a target for the treatment of osteoporosis
 
 
Patent Number: 7,357,929

This patent covers the inhibition of placental growth factor as a method of treating osteoporosis.  The one issued claim is restricted to inhibition of placental growth factor using an antibody or fragments of the antibody.

The inventor demonstrated inhibition of bone resorption in an animal model, as well as in vitro using anti-placental growth factor antibodies. Interestingly in the examples the use of mesenchymal stem cells together with this antibody are also described. 

 

Ask a question OR leave your comments.

 


  Expanding Hematopoietic Stem Cells by Removing Inhibitors

Sunday April 20th, 2008 @ 15:22:22 EST

The desire to expand hematopoietic stem cells is not only a basic research accomplishment but would allow for widespread use of autologous stem cells, as well as expand the utilization of cord blood stem cells which are usually of concern due to the relatively low stem cell content.

Various methods of expanding hematopoietic stem cells exist, for example, treatment with histone deacetylase inhibitors, culture in various cytokine cocktails, or treatment with chelating agents. Unfortunately, besides at a basic level, little is known about the actual mechanisms by which stem cells self renew. Recently Dr. Michael Clarke's group published a paper (Akala et al. Long-term haematopoietic reconstitution by Trp53(-)(/-)p16(Ink4a)(-/-)p19(Arf-)(/-) multipotent progenitors Nature April 2008) shedding some light on this matter. As an aside, this is the same Dr. Clarke whose technologies were commercialized by OncoMed in the area of tumor stem cells.

Dr. Clarke's group previously demonstrated that the polycomb gene Bmi-1 is essential for hematopoietic stem cell renewal (Park et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
Nature. 2003 May 15;423(6937):302). Subsequently other groups have demonstrated that Bmi-1 is involved in adult but not embryonic stem cell self-renewal. One of the mechanisms by which Bmi-1 maintains self-renewal is by suppressing the cell cycle inhibitors p16Ink4a (p16) and p19Arf (p19). This is very interesting since both of these genes have been demonstrated to be accurate biomarkers of aging ! (Krishnamurthy et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114:1299).

In the current paper, Dr. Clarke generated mice that lack p53 as well as p16 and 19. Interesting these mice has a ten fold increase hematopoietic stem cells capable of reconsituting other repients. Additionally this striking increase in hematopoietic stem cell activity was correlated with increased cells expressing the surface phenotype of early hematopoietic stem cells.

This finding is of great interest since it suggests that techniques such as RNA interference may be useful in "suppressing suppressors" of stem cell self renewal and thus allowing for the generation of novel methods of expanding autologous stem cells without inducing differentiation.

Ask a question OR leave your comments.

Read more StemCellPatents.com News
 


  PATENTS - RECENT ACTIVITY  
  Hepatocytes for therapy and drug screening made from embryonic... | 20
 


  RECENTLY ADDED PATENTS  
  Placental growth factor as a target for the treatment of osteoporosis (7,357,929)
Assignee | Inventor | Ask a question OR leave your comments
 
  Device and method for culturing cells (7,358,082)
Assignee | Inventor | Ask a question OR leave your comments
 
  Method for rapid generation of mature dendritic cells (7,354,909)
Assignee | Inventor | Ask a question OR leave your comments
 
  Generating vascular smooth muscle cells in vitro from ES cells (7,354,763)
Assignee | Inventor | Ask a question OR leave your comments
 
  High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation (7,354,729)
Assignee | Inventor | Ask a question OR leave your comments
 
  Musculo-skeletal implant having a bioactive gradient (7,351,423)
Assignee | Inventor | Ask a question OR leave your comments
 
  Efficient nuclear transfer with primordial gametes (7,351,876)
Assignee | Inventor | Ask a question OR leave your comments
 
  Myocardial stimulation (7,349,740)
Assignee | Inventor | Ask a question OR leave your comments
 
  Methods of treatment of hematopoietic disorders (7,347,999)
Assignee | Inventor | Ask a question OR leave your comments
 
  Antigen modified cancer cell vaccines for cancer therapy (7,348,015)
Assignee | Inventor | Ask a question OR leave your comments
 
  View all 1280 Stem Cell Patents on StemCellPatents.com  


  LATEST NEWS  
  Expanding Hematopoietic Stem Cells by Removing Inhibitors
4 hours ago
 
  "I need blood" says the embryoid body
April 13th
 
  Stem Cell Cytokines Preventing Ischemia Reperfusion
April 12th
 
  Treating back pain with mesenchymal stem cells
April 12th
 
  Clinical trial for diabetes using autologous cord blood
April 1st
 
  Read more news on StemCellPatents.com  


  LATEST JOBS POSTS  
  Patent Proscecution Technology Specialist or Scientific Advisor
Crescent Strategic Resources
 
  Attorney- Patent Litigation Associate
Crescent Strategic Resources
 
  View the StemCellPatents.com Job Board

 

 

 

We thank-you again for supporting StemCellPatents.com






------------------------------------------------------------
To unsubscribe, click here.
Delivered: Sunday April 20th, 2008 @ 19:40:21 EST
 
Google

Any Comments ?.......

E-mail: manojhind2001us@gmail.com
Google
 

World Time